1 completed, 1 withdrawn. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow Stage IVB Prostate Cancer: new trials by email Literature Review of Stage IVB Prostate Cancer trials Research Report on Stage IVB Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Lutetium Lu 177-PSMA-617, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | University of California, San Francisco | 43 | 2019-05-10 | 2025-02-25 |
| Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), Radical Prostatectomy - Stage III Prostate Cancer, Stage IIIA Prostate Cancer | Phase 1 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-12-24 | 2025-04-29 |
Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Prostatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2)
CTLA-4 Antigen (1) · Ipilimumab (1) · Pluvicto (1) · Radiosurgery (1) · cemiplimab (1) · pembrolizumab (1)
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of California, San Francisco (1)
United States (1)
Adam Dicker, MD (1) · Rahul Aggarwal, MD (1)
R01CA229354 (1)